Hjem › Blodcancer › Massachusetts
Blodcancer kliniske forsøg i Massachusetts
26 studier for Blodcancer søger deltagere på steder i Massachusetts.
Byer i Massachusetts
Officiel studietekst (engelsk)
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
- Dana Farber Cancer Institute, Boston
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT06697184Multidisciplinary Intervention for Adults With Chronic Graft-versus-host Disease
- Massachusetts General Hospital, Boston
Rekrutterer
Alder 18 og opefter · Alle køn · Opdateret 24. sep. 2026 · NCT06910969Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 23. sep. 2026 · NCT03816345Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
- Brigham and Women's Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 17. sep. 2026 · NCT04242095SURGE: Supporting Utility and Representation in Genomics-based Cancer Trial Enrollment (Intervention)
- Dana Farber Cancer Institute, Boston
- Dana-Farber Cancer Institute at St. Elizabeth's Medical Center, Brighton
- Dana-Farber Cancer Instiute - Merrimack Valley, Methuen
Rekrutterer
Alder 18 og opefter · Alle køn · Opdateret 16. sep. 2026 · NCT05375643(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- Dana-Farber Cancer Institute, Boston
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 15. sep. 2026 · NCT04996875Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- Massachusetts General Hospital, Boston
RekruttererFase 1/2
Alder 12 og opefter · Alle køn · Opdateret 3. sep. 2026 · NCT04588922Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of Massachusetts, Worcester
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 20. aug. 2026 · NCT07007312Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Beth Israel Deaconess Medical Center, Boston
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 20. aug. 2026 · NCT06001788InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
- Dana Farber Cancer Institute, Boston
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
Alle aldre · Alle køn · Opdateret 17. aug. 2026 · NCT05463796PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
- Brigham and Women's Hospital, Boston
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 4. aug. 2026 · NCT06665100Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)
- Dana-Farber Cancer Institute, Boston
RekruttererFrivillige med god helbredstilstand velkomne
Alder 18 og opefter · Alle køn · Opdateret 16. jul. 2026 · NCT06469307Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies
- Tufts Medical Center, Boston
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 13. jul. 2026 · NCT06652633A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Tufts Medical Center, Boston
- Beth Israel Deaconess, Boston
- Dana Farber Cancer Institute, Boston
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 6. jul. 2026 · NCT01351545IVIG for Infection Prevention After CAR-T-Cell Therapy
- Massachusetts General Hospital Cancer Center, Boston
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 29. jun. 2026 · NCT05952804Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
- Dana-Farber Cancer Institute, Boston
- Dana Farber Cancer Institute at St. Elizabeth's, Brighton
- Dana Farber Cancer Institute at Merrimack Valley, Methuen
- og 2 flere
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 7. maj 2026 · NCT02269592Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- Dana Farber Cancer Institute, Boston
RekruttererFase 1
Alder 13 og opefter · Alle køn · Opdateret 5. maj 2026 · NCT04771572Feasibility and Acceptability of Primary Palliative Care Intervention in Patients Undergoing Hematopoietic Stem Cell Transplantation
- Massachusetts General Hospital, Boston
Rekrutterer
Alder 18 og opefter · Alle køn · Opdateret 24. apr. 2026 · NCT06676852Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
- Massachusetts General Hospital Cancer Center, Boston
Rekrutterer
Alder 18 og opefter · Alle køn · Opdateret 21. apr. 2026 · NCT05646576CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Dana Farber Cancer Institute, Boston
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 16. apr. 2026 · NCT03328078A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Massachusetts General Hospital, Boston
- UMass Chan Medical School, Worcester
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 13. mar. 2026 · NCT05735184A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 5. feb. 2026 · NCT07148180BMT-CARE: Psychosocial Intervention for Transplant Caregivers
- Massachusetts General Hospital Cancer Center, Boston
Rekrutterer
Alder 18 og opefter · Alle køn · Opdateret 15. okt. 2025 · NCT06472089HEME Home Transfusion Program
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Rekrutterer
Alder 18 og opefter · Alle køn · Opdateret 17. sep. 2025 · NCT06487247Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
- Dana-Farber Cancer Institute, Boston
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 15. apr. 2025 · NCT06462365Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Dana-Farber Cancer Institute, Boston
RekruttererFase 1
Alder 1 til 21 · Alle køn · Opdateret 6. dec. 2024 · NCT05476770Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.